Michael G. King Jr. - 21 Feb 2024 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Michael G. King, Jr.
Issuer symbol
SABS
Transactions as of
21 Feb 2024
Net transactions value
$0
Form type
4
Filing time
23 Feb 2024, 16:45:19 UTC
Previous filing
30 Nov 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SABS Employee Stock Option (right to buy) Award $0 +115,000 $0.000000 115,000 21 Feb 2024 Common Stock 115,000 $5.17 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents options to purchase shares of common stock pursuant to the Company's 2014 Equity Incentive Plan.
F2 The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.